Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-20
2011-11-29
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S017700, C514S020800, C514S021300, C514S021600, C514S021700
Reexamination Certificate
active
08067369
ABSTRACT:
This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions.
REFERENCES:
patent: 4587046 (1986-05-01), Goodman et al.
patent: 5198420 (1993-03-01), Donahoe et al.
patent: 5556757 (1996-09-01), Alstyne et al.
patent: 5767240 (1998-06-01), Brenneman et al.
patent: 6113947 (2000-09-01), Cleland et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6613740 (2003-09-01), Gozes et al.
patent: 6649411 (2003-11-01), Gozes et al.
patent: 6933277 (2005-08-01), Brenneman et al.
patent: 7264947 (2007-09-01), Gozes et al.
patent: 7384908 (2008-06-01), Brenneman et al.
patent: 7427590 (2008-09-01), Brenneman et al.
patent: 7427598 (2008-09-01), Spong et al.
patent: 7452867 (2008-11-01), Gozes et al.
patent: 7863247 (2011-01-01), Brenneman et al.
patent: 2002/0028763 (2002-03-01), Shade et al.
patent: 2002/0111301 (2002-08-01), Brenneman et al.
patent: 2003/0166544 (2003-09-01), Clark et al.
patent: 2004/0053313 (2004-03-01), Gozes et al.
patent: 2007/0054847 (2007-03-01), Gozes et al.
patent: 2008/0194488 (2008-08-01), Gozes et al.
patent: 2009/0124543 (2009-05-01), Gozes et al.
patent: 2009/0137469 (2009-05-01), Gozes et al.
patent: 2009/0203615 (2009-08-01), Spong et al.
patent: 2009/0247457 (2009-10-01), Brenneman et al.
patent: 2010/0216723 (2010-08-01), Gozes et al.
patent: 1 206 489 (2004-05-01), None
patent: WO 92/18140 (1992-10-01), None
patent: WO 96/11948 (1996-04-01), None
patent: WO 98/35042 (1998-08-01), None
patent: WO 00/27875 (2000-05-01), None
patent: WO 00/53217 (2000-09-01), None
patent: WO 01/12654 (2001-02-01), None
patent: WO 01/92333 (2001-12-01), None
patent: WO 2004/080957 (2004-09-01), None
Levkovitch-Verbin 2002 (Investigative Ophthalmology & Visual Science 43:402-410).
Nork et al. 2000 (Arch Ophthalmol 118:1242-1250).
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides, vol. 71, No. 2, (Aug. 15, 1997).
Bedikian, Agop Y., et al., “Phase II Trial of Docetaxel in Patients with Advanced Cutaneous Malignant Melanoma Previously Untreated with Chemotherapy;”Journal of Clinical Oncology13(12): 2895-2899 (Dec. 1995).
Bassan, M. et al. “Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry72: 1283-1293 (1999).
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts, vol. 24, Part 1, p. 1043 (1998).
Brenneman, D.E. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation97:2299-2307 (1996).
Brenneman et al. “Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide,”Nature335:639 (1988).
Brenneman et al. “N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures ”Dev. Brain Res. 51:63 (1990).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Brenneman, D.E. et al. “Activity-Dependent Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics285:619-627 (1998).
Brenneman, D.E., et al.; “Protective Peptides Derived from Novel Glial Proteins;”Biochemical Society Transactions28(4): 452-455 (2000).
Chiba, Tomohiro et al.; “Neuroprotective Effect of Activity-Dependent Neurotrophic Factor Against Toxicity From Familial Amyotrophic Lateral Sclerosis-Linked Mutant SOD1 in Vitro and in Vivo,”Journal of Neuroscience Research78:542-552 (2004).
Chiba Tomohiro, et al., “Development of a Femtomolar-Acting Humanin Derivative Named Colivelin by Attaching Activity-Dependent Neurotrophic Factor to its N Terminus: Characterization of Colivelin-Mediated Neuroprotection against Alzheimer's Disease-Relevant Insults in Vitro and in Vivo;”The Journal of Neuroscience25(44): 10252-10261 (Nov. 2, 2005).
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation99:2837-2841 (1997).
Divinski, Irina, et al ., “A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes Against Zinc Intoxication;”The Journal of Biological Chemistry279(27):28531-28538 (Jul. 2, 2004).
Furman, Sharon, et al.; “Subcellular Localization and Secretion of Activity-Dependent Neuroprotective Protein in Astrocytes,”Neuron Glia Biology1:193-199 (2004).
GenBank Accession No. AB018327 from the DNA Data Bank of Japan (DDBJ) (released Nov. 17, 1998).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience Letters, Supplement 48 S1-S60, p. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2249 (1997).
Glazner, G.W. at al. “Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth and Development,”Anat. Embryol. 200:65-71 (1999).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience7:235-244 (1996).
Gozes, I. et al. “Stearyl-Norleucine-Vasoactive i/Intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology134:2125 (1994).
Gozes, I. et al. “Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics273:161-167 (1995).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci. USA93:427-432 (1996).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity.”Developmental Brain Research99:167-175 (1997).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience Letters, Supplement 48 S1-S60, p. S21 (1997).
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology33:329-342 (1997).
Gozes, I. et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts, vol. 23, Part 2, p. 2250 (1997).
Gozes, et al., “A Novel Signaling Molecule for Neuropeptide Action: Activity-dependent Neuroprotective Protein”;Annals of the New York Academy of Sciences897:125-135 (1999).
Gozes, I. et al. “Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water mazeȁ
Belkin Michael
Gozes Illana
Kilpatrick Townsend & Stockton LLP
Kolker Daniel E
Ramot at Tel-Aviv University
LandOfFree
Protection of the retina against laser injury by NAP and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection of the retina against laser injury by NAP and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection of the retina against laser injury by NAP and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4290039